Specialty Pharma: Guide to Success at the New Frontier

Recently catapulted into the pharmaceutical industry limelight, Specialty Pharma may well be the solution to many of Big Pharma's current woes. Its success driven largely by astute manipulation of the business and market issues that currently plague Big Pharma, Specialty Pharma has shown the potential to capture and firmly command market spaces once dominated by Big Pharma. Get the Answers You Need to Shape Your Strategy The emergence of Specialty Pharma as a market force occurred as Big Pharma and Mid Pharma began to consolidate. What strategies will Specialty Pharma pursue as it continues to capitalize on Big Pharma's looming market problems? Patents have become a trapdoor for both Big Pharma and Mid Pharma alike; once patents expire, these companies fi nd themselves hanging in a market abyss. What methods are Specialty Pharma using to sidestep such patent expiry pitfalls? What specifi c markets or patient cohorts are receiving attention from Specialty Pharma? Value-for-money is the mantra of today's knowledgeable and organized health care customers-a challenge for Specialty Pharma, which has received condemnation over its pricing of orphan drugs. How can Specialty Pharma best present its pricing practices to an increasingly informed and skeptical consumer audience? Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Market drivers: business factors and issues that are driving the transformation of the pharma market.

Market overview: market conditions that contributed to the emergence and subsequent growth of Specialty Pharma.

Success and uncertainty: how Specialty Pharma’s success has altered its market space, and how these companies need to respond to the changing marketplace.

Specialty Pharma business models: 11 business models, with examples of companies that utilize them.

Challenges: threats to the continued growth of the Specialty Pharma sector.

Market outlook: opportunities and strategies for Specialty Pharma companies to succeed in today’s changing pharma business environment.

Companies Mentioned in This Spectrum Report:

Abbott
Ache
Actavis
Alcon
Allergan
Almirall Prodespharma
Altana Pharma
Anthrogenesis
AstraZeneca
Barr Pharmaceuticals
Basilea Pharmaceutica
BioMarin Pharmaceutical
Cambridge Laboratories
Carter-Wallace
(now MedPointe Pharmaceuticals)
Celgene
Cell Therapeutics
Cephalon
Chiesi Farmaceutici
Connetics
Dako
Dermal Laboratories
Eli Lilly and Company
Endo Pharmaceuticals
Ferring Pharmaceuticals
Forest Laboratories
Galderma
Galen Holdings
Gilead Sciences
GlaxoSmithKline
Gruenenthal
Hermal Kurt Herrmann
Hoffmann-La Roche
Hospira
ICOS
Idun Pharmaceuticals
King Pharmaceuticals
Laboratorios Bago
Laboratorios Esteve
Lemmon Pharmacal
Ligand Pharmaceuticals
Link Pharmaceuticals
H. Lundbeck
Mayne Pharma
Medac
Medimmune
Menarini Group
MSD-Chibret
Myogen
New River
Pharmaceuticals
Novartis
Noven Pharmaceuticals
Nycomed
Orphan Europe
Pain Therapeutics
Pfizer
Pharmion
The Purdue Frederick
Company
Ranbaxy Laboratories
Ratiopharm
Recordati
Roche
Rosemont Pharmaceuticals
RxKinetix
Salmedix
Sanofi -Aventis
Shire
Signal Pharmaceuticals
SkyePharma
Solvay Pharmaceuticals
Stiefel Laboratories
Teva Pharmaceutical
Industries
Teva Pharmaceuticals USA
TransKaryotic Therapies
UCB
Vicuron Pharmaceuticals